AOD vs GLP-1 GLP-1 agonists (semaglutide, tirzepatide) are our primary medical weight-loss lane with the strongest evidence
Saccharomyces cerevisiae is used as a host to produce our EV1 Peptide
Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and meta-analysis (BMJ)
Visual indicators of BPC-157 degradation include a lyophilized cake that has become translucent, collapsed, or discolored from white to yellow or brown, which suggests oxidation or Maillard-type reactions with trace contaminants
can help clarify the right next step, and for some patients that includes a transition into performance testing, structured strength work, or a more comprehensive Medical Weight Loss Program
These individualized care strategies highlight how tailored approaches can make GLP-1 therapy a safe and effective option for managing CKD